Roundhill GLP-1 & Weight Loss ETF (OZEM US) stock market data APIs

Roundhill GLP-1 & Weight Loss ETF Financial Data Overview

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.

Get Roundhill GLP-1 & Weight Loss ETF data using free add-ons & libraries

All libraries and code examples

---

All add-ons

End-of-day & Earnings data

Roundhill GLP-1 & Weight Loss ETF News

New

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

4 weeks ago

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver di...

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

1 month ago

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes ...

Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs

1 month ago

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NVO) tumbled 22% Tuesday after the company slashed its 2025 outlook and announced a CEO change, sending shockwaves through a range of ETFs tied ...

Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected

3 months ago

Photo by Clay Banks via Unsplash GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment ...

• Flexibility: No long-term commitments, just a minimum of one month
• Instant access: Get your API key and instructions within seconds of subscribing
• Price stability: Locked-in rates for subscribed users, never changing